Chief Medical Officer and Executive Vice President
Cited in UK press coverage of health & social care
2 citations
Across 2 topics, first on 27 Aug 2026.
Dr Julie R. Gralow, MD, FACP, FASCO, is the Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology (ASCO), a role she has held since February 2021. She is a breast medical oncologist and Professor (emeritus) of Medical Oncology and Global Health at the University of Washington School of Medicine, where she directed the Breast Medical Oncology programme for more than 25 years. Prior to joining ASCO full-time, she was the Jill Bennett Endowed Professor of Breast Cancer at the University of Washington and Director of Breast Medical Oncology at the Seattle Cancer Care Alliance. In her role as ASCO CMO, she directly oversees ASCO's Center for Research and Analytics, Policy and Advocacy Department, Care Delivery Department, and Center for Global Impact, and serves as a public spokesperson for ASCO. She is known for commenting on major oncology trial results with relevance to UK health policy, including the NHS-Galleri multi-cancer early detection trial presented at ASCO in 2026. She founded the Women's Empowerment Cancer Advocacy Network (WE CAN) to support cancer advocacy in low- and middle-income countries, and received the ASCO Humanitarian Award in 2018 for that work.
Cited on
Stated areas of expertise
“While the Galleri-NHS study results show some encouraging trends toward tumour downstaging, it is important to recognise that the trial did not statistically reduce late-stage cancers by its predefined primary endpoint.”
Asco's chief medical officer and executive vice-president · Hospital discharge / bed-blocking · 27 Aug 2026 · Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim ↗
“It was a "gamechanger". She added: "I've heard this study described as a home run. I would actually say it's a grand slam."”
Asco's chief medical officer and executive vice-president · Cancer · 27 Aug 2026 · Daily pill can double survival time for world’s deadliest cancer, trial shows ↗
Organisational contact points only, each taken from a page the organisation publishes itself. No personal or direct contact details are held or shown.
Doctors, nurses, allied health professionals and other registered clinicians quoted in a clinical capacity. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.